Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 2/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | DNTT | P04053 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858515 | 1.00 | AKT1 (0.36) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL19326774 | 1.00 | AKT1 (0.36) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL13858353 | 1.00 | AKT1 (0.36) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL19326776 | 1.00 | AKT1 (0.36) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL13858507 | 1.00 | AKT1 (0.36) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL13858527 | 1.00 | AKT1 (0.36) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL5436141 | 0.98 | AKT1 (0.34) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL1537221 | 0.98 | AKT1 (0.34) | AKT1HPSEPOLBFASNPOLA1 | |
| SCHEMBL18334882 | 0.80 | IDUA (0.33) | — | |
| SCHEMBL3804519 | 0.78 | GAA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4047023-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2022-08-24 | — | — | EP | claimed |
| EP-2922876-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2018-10-10 | — | — | EP | claimed |
| EP-2710031-B9 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2710031-B1 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2017-09-13 | — | — | EP | claimed |
| CN-103796666-A | Improved Peptide Drugs | EUMEDERIS PHARMACEUTICALS INC | 2014-05-14 | — | — | CN | claimed |
| EP-4286400-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2022-11-03 | — | — | US | disclosed |
| EP-4047023-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3444281-B1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20210077629-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | MEDERIS DIABETES LLC (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3566711-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10420844-B2 | Peptide pharmaceuticals | MEDERIS DIABETES LLC (US) | 2019-09-24 | — | — | US | disclosed |
| US-10005817-B2 | Peptide pharmaceuticals | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20150307550-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2015-10-29 | — | — | US | disclosed |
| EP-2922877-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| US-20150031630-A1 | Peptide Pharmaceuticals | HERCULES CAPITAL, INC., AS AGENT | 2015-01-29 | — | — | US | disclosed |
| WO-2014081864-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| CN-103796666-A | Improved Peptide Drugs | EUMEDERIS PHARMACEUTICALS INC | 2014-05-14 | — | — | CN | disclosed |
| EP-2709645-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158962-A2 | IMPROVED PEPTIDE PHARMACEUTICALS | EUMEDERIS PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | AKT1 4244/4885HPSE 269/4885POLB 3798/4885 |
| US-20150031630-A1 | Peptide Pharmaceuticals | PTMS, DNPEP, ANPEP | AKT1 4244/4885HPSE 269/4885POLB 3798/4885 |
| US-10420844-B2 | Peptide pharmaceuticals | PTMS, DNPEP, ANPEP | AKT1 4244/4885HPSE 269/4885POLB 3798/4885 |
| US-10005817-B2 | Peptide pharmaceuticals | PTMS, DNPEP, ANPEP | AKT1 4244/4885HPSE 269/4885POLB 3798/4885 |
| US-20150307550-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | AKT1 4538/4885HPSE 218/4885POLB 3955/4885 |
| US-20210077629-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | AKT1 4538/4885HPSE 218/4885POLB 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.